CD36 single nucleotide polymorphism is associated with variation in low-density lipoprotein-cholesterol in young Japanese men

Biomarkers

Volumn 14, Issue 4, 2009, Pages 207-212

  Morii, Toshiyuki ^a   Ohno, Yoichi ^a,b   Kato, Norihiro ^c   Hirose, Hiroshi ^a   Kawabe, Hiroshi ^a   Hirao, Keiichi ^a   Eguchi, Takashi ^a   Maruyama, Tatsuya ^a   Hayashi, Matsuhiko ^a   Saito, Ikuo ^a   Yazaki, Yoshio ^c   Saruta, Takao ^a  

^a KEIO UNIVERSITY   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

CD36; LDL cholesterol; Single nucleotide polymorphism

Indexed keywords

CD36 ANTIGEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; SCAVENGER RECEPTOR;

3' UNTRANSLATED REGION; ADULT; ALLELE; ARTICLE; CD36 GENE; CHOLESTEROL BLOOD LEVEL; FOAM CELL; GENE; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; JAPANESE; MACROPHAGE; MALE; NORMAL HUMAN; SINGLE NUCLEOTIDE POLYMORPHISM; ASIAN; BLOOD; GENETICS; JAPAN;

ANTIGENS, CD36; ASIAN CONTINENTAL ANCESTRY GROUP; CHOLESTEROL, LDL; HUMANS; JAPAN; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; YOUNG ADULT;

EID: 68549104437     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.1080/13547500902811274     Document Type: Article

References (31)

1. Aitman TJ. (2001). CD36, insulin resistance, and coronary heart disease. Lancet 357:651-652
2. Aitman TJ, Glazier AM, Wallace CA, Cooper LD, Norsworthy PJ, Wahid FN, Al-Majali KM, Trembling PM, Mann CJ, Shoulders CC, Graf D, St Lezin E, Kurtz TW, Kren V, Pravenec M, Ibrahimi A, Abumrad NA, Stanton LW, Scott J. (1999). Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nature Genetics 21:76-83.
3. Berenson GS, Wattigney WA, Tracy RE, Newman WP 3rd, Srinivasan SR, Webber LS, Dalferes ER Jr, Strong JP. (1992). Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors Bogalusa Heart Study). Am J Cardiol 70:851-858
4. Calvo D, Gomez-Coronado D, Lasuncion MA, Vega MA. (1997). CLA-1 is an 85-kD plasma membrane glycoprotein that acts as a high-affinity receptor for both native (HDL, LDL, and VLDL) and modified (OxLDL and AcLDL) lipoproteins. Arterioscler Thromb Vasc Biol 17:2341-2349
5. Calvo D, Gomez-Coronado D, Suarez Y, Lasuncion MA, Vega MA. (1998). Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL. J Lipid Res 39:777-788
6. De Villiers WJ, Cai L, Webb NR, De Beer MC, Van der Westhuyzen DR, De Beer FC. (2001). CD36 does not play a direct role in HDL or LDL metabolism. J Lipid Res 42:1231-1238
7. Esler M, Rumantir M, Wiesner G, Kaye D, Hastings J, Lambert G. (2001). Sympathetic nervous system and insulin resistance: from obesity to diabetes. Am J Hypertens 14:304-9S.
8. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, Silverstein RL. (2000). Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 105:1049-1056
9. Furuhashi M, Ura N, Nakata T, Shimamoto K. (2003). Insulin sensitivity and lipid metabolism in human CD36 deficiency. Diabetes Care 26:471-474
10. Greenwalt DE, Lipsky RH, Ockenhouse CF, Ikeda H, Tandon NN, Jamieson GA. (1992). Membrane glycoprotein CD36: a review of its roles in adherence, signal transduction, and transfusion medicine. Blood 80:1105-1115
11. Ibrahimi A, Bonen A, Blinn WD, Hajri T, Li X, Zhong K, Cameron R, Abumrad NA. (1999). Muscle-specific overexpression of FAT/ CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin. J Biol Chem 274:26761-26766
12. Ikeda H, Mitani T, Ohnuma M, Haga H, Ohtzuka S, Kato T, Nakase T, Sekiguchi S. (1989). A new platelet-specific antigen, Naka, involved in the refractoriness of HLA-matched platelet transfusion. Vox Sang 57:213-217
13. Kohen-Avramoglu R, Theriault A, Adeli K. (2003). Emergence of the metabolic syndrome in childhood: an epidemiological overview and mechanistic link to dyslipidemia. Clin Biochem 36:413-420
14. Koonen DP, Jacobs RL, Febbraio M, Young ME, Soltys CL, Ong H, Vance DE, Dyck JR. (2007). Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes 56:2863-2871
15. Lepretre F, Cheyssac C, Amouyel P, Froguel P, Helbecque N. (2004a). A promoter polymorphism in CD36 is associated with an atherogenic lipid profile in a French general population. Atherosclerosis 173:375-377
16. Lepretre F, Linton KJ, Lacquemant C, Vatin V, Samson C, Dina C, Chikri M, Ali S, Scherer P, Seron K, Vasseur F, Aitman T, Froguel P. (2004b). Genetic study of the CD36 gene in a French diabetic population. Diabetes Metab 30:459-463
17. Lepretre F, Vasseur F, Vaxillaire M, Scherer PE, Ali S, Linton K, Aitman T, Froguel P. (2004c). A CD36 nonsense mutation associated with insulin resistance and familial type 2 diabetes. Hum Mutat 24:104.
18. Lewis GF, Carpentier A, Adeli K, Giacca A. (2002). Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 23:201-229
19. Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G. (1995). Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 95:158-166
20. Lewis GF, Vranic M, Harley P, Giacca A. (1997). Fatty acids mediate the acute extrahepatic effects of insulin on hepatic glucose production in humans. Diabetes 46:1111-1119
21. Lindmark S, Wiklund U, Bjerle P, Eriksson JW. (2003). Does the autonomic nervous system play a role in the development of insulin resistance? A study on heart rate variability in first-degree relatives of Type 2 diabetes patients and control subjects. Diabet Med 20:399-405.
22. Morii T, Ohno Y, Hirose H, Kawabe H, Ogata T, Hirao K, Eguchi T, Maruyama T, Kanno Y, Hayashi M, Saito I, Saruta T. (2005). Cellular insulin resistance in Epstein-Barr virus-transformed lymphoblasts from young insulin-resistant Japanese men. Metabolism 54:370-375
23. Pesole G, Mignone F, Gissi C, Grillo G, Licciulli F, Liuni S. (2001). Structural and functional features of eukaryotic mRNA untranslated regions. Gene 276:73-81.
24. Podrez EA, Byzova TV, Febbraio M, Salomon RG, Ma Y, Valiyaveettil M, Poliakov E, Sun M, Finton PJ, Curtis BR, Chen J, Zhang R, Silverstein RL, Hazen SL. (2007). Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med 13:1086-1095
25. Pravenec M, Landa V, Zidek V, Musilova A, Kren V, Kazdova L, Aitman TJ, Glazier AM, Ibrahimi A, Abumrad NA, Qi N, Wang JM, St Lezin EM, Kurtz TW. (2001). Transgenic rescue of defective Cd36 ameliorates insulin resistance in spontaneously hypertensive rats. Nat Genet 27:156-158
26. Rac ME, Safranow K, Poncyljusz W. (2007). Molecular basis of human CD36 gene mutations. Mol Med 13:288-296
27. Watanabe K, Sekiya M, Tsuruoka T, Funada J, Kameoka H, Miyagawa M, Kohara K. (1999). Relationship between insulin resistance and cardiac sympathetic nervous function in essential hypertension. J Hypertens 17:1161-1168
28. Yamamoto N, Ikeda H, Tandon NN, Herman J, Tomiyama Y, Mitani T, Sekiguchi S, Lipsky R, Kralisz U, Jamieson GA. (1990). A platelet membrane glycoprotein (GP) deficiency in healthy blood donors: Naka- platelets lack detectable GPIV (CD36). Blood 76:1698-1703
29. Yanai H, Chiba H, Morimoto M, Abe K, Fujiwara H, Fuda H, Hui SP, Takahashi Y, Akita H, Jamieson GA, Kobayashi K, Matsuno K. (2000). Human CD36 deficiency is associated with elevation in low-density lipoprotein-cholesterol. Am J Med Genet 93:299-304.
30. Zhao Z, De Beer MC, Cai L, Asmis R, De Beer FC, De Villiers WJ, Van der Westhuyzen DR. (2005). Low-density lipoprotein from apolipoprotein E-deficient mice induces macrophage lipid accumulation in a CD36 and scavenger receptor class A-dependent manner. Arterioscler Thromb Vasc Biol 25:168-173
31. Zieske AW, Malcom GT, Strong JP. (2002). Natural history and risk factors of atherosclerosis in children and youth: the PDAY study. Pediatr Pathol Mol Med 21:213-237